<DOC>
	<DOCNO>NCT00727753</DOCNO>
	<brief_summary>The objective study evaluate effect 2 intravitreal injection Ranibizumab Avastin endothelial function subject neovascular macular degeneration compare patient dry AMD .</brief_summary>
	<brief_title>VEGF-antagonism Endothelial Function Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Inclusion Criteria active treatment : Age : 50 80 year Diagnosis neovascular macular degeneration suitable intravitreal antiVEGF therapy Stable medication general condition least 1 month Written inform consent participation study Inclusion criterion control : Age : 50 80 year Diagnosis `` dry '' AMD `` dry '' AMD define least AgeRelatedEyeDiseaseStudy ( AREDS ) category 2 eye evidence neovascularization either eye Stable medication general condition least 1 month Written inform consent participation study Exclusion Criteria subject : Myocardial infarction , unstable angina , stroke within 3 month prior study entry Thoracic cardiac surgery and/or coronary intervention/revascularisation procedure ( within 3 month randomization ) Uncontrolled symptomatic congestive heart failure ( NHYA &gt; II ) last 4 week prior study Renal insufficiency ( Creatinine Clearance &lt; 50ml/min ) Ventricular tachyarrhythmias Poorly control hypertension , define rest blood pressure â‰¥ 160/100 mmHg Symptomatic hypotension Long act nitrate Smoking ( &gt; 5 Zig./d ) Diabetes mellitus Dyslipidemia ( LDLcholesterol &gt; 4.5 mmol/l ) Liver disease ( ALT AST &gt; 3x ULN ) Alcohol drug abuse Hypersensitivity active substance excipients Active suspect ocular periocular infection Patients active severe intraocular inflammation Malignancy ( unless heal remission &gt; 5 year ) Disease systemic inflammation ( e.g . rheumatoid arthritis , M. Crohn ) Participation another study within last month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Macular Degeneration</keyword>
	<keyword>Age-Related Maculopathies</keyword>
</DOC>